|
Synonyms: APOC-III antisense inhibitor | ISIS 304801 | ISIS-APOCIIIRx | Waylivra®
volanesorsen is an approved drug (EMA (2019))
Compound class:
Nucleic acid
Comment: Volanesorsen is an antisense oligonucleotide (ASO) designed to reduce levels of apolipoprotein C-III (APOC3) in patients with elevated blood triglyceride levels [3]. Reducing triglycerides via APOC3 could be beneficial in patients with inherited hypertriglyceridemia (e.g. those with familial chylomicronemia syndrome, FCS) [1]. The role of APOC3 in hypertriglyceridemia and the effects APOC3 ASO use are reviewed in [5].
HELM annotation for this RNA (from PubChem) is RNA1{[MOE](A).[sp][MOE](G).[sp][MOE]([5meC]).[sp][MOE](T).[sp][MOE](T).[sp][dR]([5meC]).[sp][dR](T).[sp][dR](T).[sp][dR](G).[sp][dR](T).[sp][dR]([5meC]).[sp][dR]([5meC]).[sp][dR](A).[sp][dR](G).[sp][dR]([5meC]).[sp][MOE](T).[sp][MOE](T).[sp][MOE](T).[sp][MOE](A).[sp][MOE](T)}$$$$. |
|
|||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Volanesorsen (ISIS 304801) was progressed to phase 3 studies in patients with hypertriglyceridemia. Both the US FDA and EMA granted volanesorsen orphan designation for the treatment of Familial Chylomicronemia Syndrome (FCS). Full EMA marketing authorisation as a treatment for hyperlipoproteinemia type I was granted in 2019 [6]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02658175 | The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome | Phase 3 Interventional | Akcea Therapeutics | ||
| NCT02300233 | The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia | Phase 3 Interventional | Ionis Pharmaceuticals, Inc. | 2 | |
| NCT02211209 | The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome | Phase 3 Interventional | Ionis Pharmaceuticals, Inc. | 4,7 | |